Results 161 to 170 of about 150,574 (342)

Malignancy Risk, Molecular Mutations, and Surgical Outcomes of Thyroid Nodules Classified as Atypia of Undetermined Significance in the Bethesda System: A Comprehensive Analysis

Cytopathology, EarlyView.
This study investigates the correlation between AUS subcategories, molecular mutations, and surgical outcomes in thyroid nodules classified as atypia of undetermined significance (AUS) under the Bethesda System for Reporting Thyroid Cytopathology.
Caroline Bourque, Gianluca Savoia, Maxine Noik, Livia Florianova, Saruchi Bandargal, Sabrina Daniela da Silva, Richard Payne, Marc Philippe Pusztaszeri   +7 more
wiley   +1 more source

Ectopic thyroid carcinoma in the left atrium in a horse

Equine Veterinary Education, EarlyView.
Summary A 25‐year‐old Irish sport horse was presented for investigation of a 7‐day history of apathy and lethargy. Clinical examination revealed tachycardia, tachypnoea, distended, pulsating jugular veins and ventral oedema. Serum biochemistry showed azotaemia.
N. Wolf, J. Schläpfer, E. Dervas, S. Soto, I. L. Piotrowski   +4 more
wiley   +1 more source

Predicting disease-specific survival in patients undergoing active surveillance for papillary thyroid carcinoma. [PDF]

World J Surg
Abstract Background American Thyroid Association guidelines support active surveillance (AS) for low‐risk papillary thyroid cancer (PTC). We developed a calculator to aid patient selection. Methods From 2004 to 2020, 148,904 PTC patients were selected from the surveillance, epidemiology, and end results (SEER) database.
Nielsen S, Kuchta K, Huang G, Zuber S, Holoubek S, Karcioglu A, Khokar A, Prinz R, Moo-Young T.   +8 more
europepmc   +2 more sources

Pathological Tumor-Node-Metastasis (pTNM) Staging for Papillary and Follicular Thyroid Carcinomas: A Retrospective Analysis of 700 Patients [PDF]

, 1997
Keh‐Chuan Loh, Francis S. Greenspan, Lauren Gee, Theodore R. Miller, P P Yeo   +4 more
openalex   +1 more source

The G protein‐coupled receptor GPR89A is a novel potential therapeutic target to overcome cisplatin resistance in NSCLC Calu1 cells

The FEBS Journal, EarlyView.
A genome‐wide CRISPR‐Cas9‐based genetic screen in cisplatin‐resistant NSCLC cells revealed 63 potential candidate genes for overcoming cisplatin resistance, including GPR89A. GPR89A, localised in the Golgi, modulates voltage‐gated anion channel activity and is involved in intracellular pH reduction.
Hale Guler Kara, Eda Dogan, Vildan Bozok, Cagdas Aktan, Ece Cakiroglu, Zuhal Eroglu, Duygu Aygunes Jafari, Kemal Sami Korkmaz, Serif Senturk, Buket Kosova   +9 more
wiley   +1 more source

The Fallacy of the Conventional Radical Neck Dissection for Papillary Carcinoma of the Thyroid

, 1957
George Crile
openalex   +2 more sources

High Prevalence of RET/PTC Rearrangements in Ukrainian and Belarussian Post-Chernobyl Thyroid Papillary Carcinomas: A Strong Correlation between RET/PTC3 and the Solid-Follicular Variant1 [PDF]

, 1999
G Thomas, H. Bunnell, Helen Cook, E. D. Williams, Alexander Nerovnya, E. D. Cherstvoy, М.D. Тronko, Bogdanova Ti, Gennaro Chiappetta, Giuseppe Viglietto, Francesca Pentimalli, Giuliana Salvatore, Alfredo Fusco, Massimo Santoro, Giancarlo Vecchio   +14 more
openalex   +1 more source

Label-free pathological subtyping of non-small cell lung cancer using deep classification and virtual immunohistochemical staining [PDF]

arXiv
The differentiation between pathological subtypes of non-small cell lung cancer (NSCLC) is an essential step in guiding treatment options and prognosis. However, current clinical practice relies on multi-step staining and labelling processes that are time-intensive and costly, requiring highly specialised expertise.
arxiv  

RET/PTCandRETTyrosine Kinase Expression in Adult Papillary Thyroid Carcinomas¹ [PDF]

, 1998
Diana Learoyd, Marinella Messina, Jan Zedenius, Ana I. Guinea, Leigh Delbridge, Bruce G. Robinson   +5 more
openalex   +1 more source

Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
ALLEGRO‐LT (NCT04006457) is an open‐label, phase 3 study investigating the long‐term safety and efficacy of ritlecitinib in patients with alopecia areata (AA). In this analysis in 449 de novo patients with AA and ≥25% scalp hair loss, ritlecitinib demonstrated clinical efficacy and had an acceptable safety profile through Month 24.
C. Tziotzios, R. Sinclair, A. Lesiak, S. Mehlis, M. Kinoshita‐Ise, A. Tsianakas, X. Luo, E. H. Law, R. Ishowo‐Adejumo, R. Wolk, M. Sadrarhami, A. Lejeune   +11 more
wiley   +1 more source